MedTrace Logo

Study of ANAVEX2-73 in Patients With Rett Syndrome

NCT03758924 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2021-01-12

No results posted yet for this study

Summary

Phase 2 safety, tolerability and efficacy study is designed as a double-blind, randomized, placebo-controlled study.

7-week placebo-controlled study of ANAVEX2-73 oral solution for the treatment of patients with RTT 18 years or older. A voluntary option will be offered for all patients who meet the exposure criteria for ANAVEX2-73 to continue a 12-week open label extension.

Conditions

Interventions

DRUG

ANAVEX2-73

Liquid oral solution

DRUG

Placebo

Liquid oral solution

Sponsors & Collaborators

  • International Rett Syndrome Foundation Rettsyndrome.org

    collaborator UNKNOWN

  • Anavex Life Sciences Corp.

    lead INDUSTRY

Principal Investigators

  • Walter Kaufmann, MD · Emory University SOM

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-28
Primary Completion
2020-10-30
Completion
2020-10-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03758924 on ClinicalTrials.gov